AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.385

-0.010-2.53%

Volume:2.89M

Turnover:1.12M

Market Cap:567.38M

PE:-6.72

High:0.400

Open:0.390

Low:0.380

Close:0.395

52wk High:0.470

52wk Low:0.222

Shares:1.47B

Float Shares:1.23B

Volume Ratio:1.25

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.057

EPS(LYR):-0.042

ROE:-61.85%

ROA:-32.10%

PB:5.74

PE(LYR):-9.12

Loading ...

Overview Company News Filings

Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives

Simply Wall St.

BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million

Immutep Posts Wider Fiscal H1 Loss, Higher Revenue

MT Newswires Live

Immutep Ltd - Hy Net Loss Attributable a$44.9 Mln

THOMSON REUTERS

Immutep Publishes Corporate Presentation on LAG-3 Immunotherapy for Cancer and Autoimmune Disease

3 ASX Penny Stocks With Market Caps Under A$600M

Simply Wall St.

Immutep Initiated at Market Outperform by Citizens

Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs

Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc

THOMSON REUTERS

Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial

MT Newswires Live

Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January

MT Newswires Live

BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update

Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study

THOMSON REUTERS

Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026

THOMSON REUTERS

Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile

THOMSON REUTERS

Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial

MT Newswires Live

Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial

MT Newswires Live

Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial

ASX Penny Stocks Spotlight: DUG Technology Among 3 Noteworthy Picks

Simply Wall St.

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.385,"timestamp":1772169120000,"preClose":0.395,"halted":0,"volume":2887018,"delay":0,"changeRate":-0.025316455696202552,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"Market Closed","change":-0.01,"latestTime":"02-27 16:12:00 AEDT","open":0.39,"high":0.4,"low":0.38,"amount":1122579,"amplitude":0.050633,"askPrice":0.385,"askSize":5089,"bidPrice":0.38,"bidSize":18572,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772406000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.395,"openAndCloseTimeList":[[1772146800000,1772168400000]],"volumeRatio":1.249507,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-32.10%","roe":"-61.85%","lyrEps":-0.042199,"volumeRatio":1.249507,"shares":1473721306,"dividePrice":0,"high":0.4,"amplitude":0.050633,"preClose":0.395,"low":0.38,"week52Low":0.222,"pbRate":"5.74","psRate":"71.61","week52High":0.47,"institutionHeld":0,"latestPrice":0.385,"committee":0.569841,"eps":-0.057294,"divideRate":0,"volume":2887018,"delay":0,"ttmEps":-0.057294,"open":0.39,"prevYearClose":0.415,"prevWeekClose":0.395,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.395,"twentyDayClose":0.395,"sixtyDayClose":0.295,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614244008","title":"Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2614244008","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614244008?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:29","pubTimestamp":1772141370,"startTime":"0","endTime":"0","summary":"Immutep H1 2026 Results: Losses Widen as Revenue Steps Up\nImmutep (ASX:IMM) has posted its H1 2026 numbers with revenue of A$6.0 million and a basic EPS loss of A$0.0305, alongside a net loss of A$44.9 million that keeps the biotech firmly in loss-making territory. Over recent halves, the company has seen revenue move from A$3.1 million in H1 2025 to A$1.9 million in H2 2025 and now A$6.0 million in H1 2026. EPS has shifted from a loss of A$0.0154 in H1 2025 to a loss of A$0.0268 in H2 2025...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-h1-2026-loss-worsening-challenges-bullish-revenue-gr","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-h1-2026-loss-worsening-challenges-bullish-revenue-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","BLSG","BK7067","BK7508","BLSX","BK4112"],"gpt_icon":0},{"id":"2614200787","title":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614200787","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614200787?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:43","pubTimestamp":1771983828,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 MillionFeb 25 (Reuters) - Immutep Ltd IMM.AX:HY TOTAL REVENUE AND OTHER INCOME A$7.7 MILLIONHY NET LOSS ATTRIBUTABLE A$44.9 MILLIONFurther company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2614072014","title":"Immutep Posts Wider Fiscal H1 Loss, Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614072014","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614072014?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:32","pubTimestamp":1771983160,"startTime":"0","endTime":"0","summary":"Immutep  reported Wednesday fiscal first-half loss of AU$0.0305 per share, compared with AU$0.0154 a year earlier.Analysts polled by FactSet expected loss of AU$0.03.Total revenue and other income for the six months ended Dec. 31, 2025, was AU$7.7 million, compared with AU$7.3 million a year earlier.The company's shares were up 1% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2614851726","title":"Immutep Ltd - Hy Net Loss Attributable a$44.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614851726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614851726?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:09","pubTimestamp":1771970941,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1CG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2613193062","title":"Immutep Publishes Corporate Presentation on LAG-3 Immunotherapy for Cancer and Autoimmune Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613193062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613193062?lang=en_us&edition=fundamental","pubTime":"2026-02-21 10:20","pubTimestamp":1771640409,"startTime":"0","endTime":"0","summary":"Immutep Ltd. released a corporate presentation outlining its LAG-3 immunotherapy pipeline, including four clinical-stage assets targeting MHC Class II and LAG-3 pathways, such as eftilagimod alfa  and IMP761. The presentation highlights the company’s registrational Phase III TACTI-004  trial in first-line non-small cell lung cancer , evaluating efti plus KEYTRUDA and chemotherapy versus KEYTRUDA and chemotherapy, with dual primary endpoints of progression-free survival and overall survival. Immutep also provides an update on trial execution, noting broad global site activation and that 378 patients had been enrolled as of 6 February 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260221:nNDL6FF7Fp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2612497372","title":"3 ASX Penny Stocks With Market Caps Under A$600M","url":"https://stock-news.laohu8.com/highlight/detail?id=2612497372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612497372?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:05","pubTimestamp":1771380305,"startTime":"0","endTime":"0","summary":"Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-krr/king-river-resources-shares/news/3-asx-penny-stocks-with-market-caps-under-a600m-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-krr/king-river-resources-shares/news/3-asx-penny-stocks-with-market-caps-under-a600m-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["WAF.AU","BK7104","BK7508","BK7045","PPL.AU","BK7061","BK7503","PPS.AU","XAO.AU","AEF.AU","BK7095","BK7058","IMM.AU","VRS.AU","HSN.AU","BK7077","KSC.AU","XJO.AU","AAL.AU","XKO.AU","BK7143","KRR.AU","BK7067","BK7016","BK7050","BK7062","MTO.AU","MXI.AU","IGL.AU","BK7506"],"gpt_icon":0},{"id":"2612688014","title":"Immutep Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2612688014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612688014?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:18","pubTimestamp":1771337880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 09:18 ET (14:18 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMMP","BK7508","BK4139","IMM.AU"],"gpt_icon":0},{"id":"2610649614","title":"Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610649614?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:03","pubTimestamp":1770721384,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbbVDC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2609459560","title":"Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459560?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:00","pubTimestamp":1770382800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA9XGGVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2609533421","title":"Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533421?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:21","pubTimestamp":1770333717,"startTime":"0","endTime":"0","summary":"Immutep  has achieved 50% of its patient enrollment target in the TACTI-004 phase three trial, testing eftilagimod alfa in combination with Merck's Keytruda and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer, according to a Friday Australian bourse filing.The trial has enrolled 378 patients across more than 140 sites in 27 countries, per the filing.It seeks to increase response rates to anti-PD-1 therapy across all PD-L1 levels while improving clinical outcomes and patient survival, the filing said.Patient enrollment and the scheduled futility analysis are proceeding as planned, with complete enrollment anticipated by the third quarter, the filling added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2607779506","title":"Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779506?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:42","pubTimestamp":1769658172,"startTime":"0","endTime":"0","summary":"Immutep  said it received around AU$30 million in upfront payment from Indian firm Dr. Reddy's Laboratories in January under its strategic collaboration for the commercialization of Eftilagimod Alfa, its drug candidate for the treatment of non-small cell lung cancer, according to a Thursday Australian bourse filing.The firm is eligible to receive up to around AU$528 million in potential milestones, plus royalties on commercial sales of the drug candidate.During the December 2025 quarter, its AIPAC-003 phase two/three trial in metastatic breast cancer enrolled 71 metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative/low patients, resistant to endocrine therapy, including cyclin-dependent kinase 4/6 inhibitors, or triple-negative breast cancer patients.Its shares fell 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2593545170","title":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545170?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:44","pubTimestamp":1766450664,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT00R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2593487707","title":"Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487707?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2593487092","title":"Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487092?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2593487002","title":"Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487002?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2593711881","title":"Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593711881","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593711881?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:48","pubTimestamp":1766364498,"startTime":"0","endTime":"0","summary":"Immutep  said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.The firm's shares fell past 1% in recent trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2591967586","title":"Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591967586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591967586?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:48","pubTimestamp":1765846096,"startTime":"0","endTime":"0","summary":"Immutep  said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2591785026","title":"Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591785026","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591785026?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:56","pubTimestamp":1765842994,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL7RvJTk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2591691009","title":"ASX Penny Stocks Spotlight: DUG Technology Among 3 Noteworthy Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591691009?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:04","pubTimestamp":1765764296,"startTime":"0","endTime":"0","summary":"As Australian shares face a challenging start to the week, influenced by global tech sector declines, investors may find themselves exploring alternative opportunities within the market. Penny stocks, often representing smaller or newer companies, continue to capture interest despite their somewhat outdated label. By focusing on those with solid financial foundations and potential for growth, these stocks can offer surprising value and stability in uncertain times.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-wgn/wagners-holding-shares/news/asx-penny-stocks-spotlight-dug-technology-among-3-noteworthy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-wgn/wagners-holding-shares/news/asx-penny-stocks-spotlight-dug-technology-among-3-noteworthy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7044","BK7055","BK7012","DUG.AU","BK7506","SSM.AU","WAF.AU","BK7067","BK7111","VRS.AU","GWA.AU","BK7508","BK7132","AAL.AU","DSK.AU","WGN.AU","BK7077","IGL.AU","EZZ.AU","BK7143","BK7016","MTO.AU","EDU.AU","BK7048","BK7128","BK7045","IMM.AU","BK7104","BK7050"],"gpt_icon":0},{"id":"2590536261","title":"Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2590536261","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590536261?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:25","pubTimestamp":1765365914,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway.\nSee our latest analysis for Immutep.\nThe recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-asximm-valuation-check-after-dr-reddys-licensing-dea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-asximm-valuation-check-after-dr-reddys-licensing-dea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","BK7067","DCF","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}